Simplified derivatives of tetrandrine as potent and specific P-gp inhibitors to reverse multidrug resistance in cancer chemotherapy
R Zeng, XM Yang, HW Li, X Li, Y Guan… - Journal of Medicinal …, 2023 - ACS Publications
Targeted inhibition of a drug efflux transporter P-glycoprotein (P-gp) is an important strategy
to reverse multidrug resistance in cancer chemotherapy. In this study, a rationally structural …
to reverse multidrug resistance in cancer chemotherapy. In this study, a rationally structural …
Reversal of P-glycoprotein-mediated multidrug resistance by the novel tetrandrine derivative W6
H Sun, XD Liu, Q Liu, FP Wang, XQ Bao… - Journal of Asian natural …, 2015 - Taylor & Francis
Overexpression of ATP-dependent efflux pump P-glycoprotein (P-gp) is the main cause of
multidrug resistance (MDR) and chemotherapy failure in cancer treatment. Inhibition of P-gp …
multidrug resistance (MDR) and chemotherapy failure in cancer treatment. Inhibition of P-gp …
In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel
X Zhu, M Sui, W Fan - Anticancer research, 2005 - ar.iiarjournals.org
Background: Multidrug resistance (MDR) is one of the major obstacles limiting the efficacy of
cancer chemotherapy. Through screening a series of natural products, we have previously …
cancer chemotherapy. Through screening a series of natural products, we have previously …
Discovery of traditional Chinese medicine monomers and their synthetic intermediates, analogs or derivatives for battling P-gp-mediated multi-drug resistance
X Ma, M Hu, H Wang, J Li - European journal of medicinal chemistry, 2018 - Elsevier
Abstract P-glycoprotein (P-gp)-mediated multi-drug resistance (MDR) is a well-documented
and predominant phenotype hampering patients' response to cancer chemotherapy …
and predominant phenotype hampering patients' response to cancer chemotherapy …
Discovery of (quinazolin-6-yl) benzamide derivatives containing a 6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline moiety as potent reversal agents against P …
W Xue, K Liu, T Zhang, G Dong, J Wang, J Wang… - European Journal of …, 2024 - Elsevier
Abstract P-glycoprotein (P-gp) is an important factor leading to multidrug resistance (MDR)
in cancer treatment. The co-administration of anticancer drugs and P-gp inhibitors has been …
in cancer treatment. The co-administration of anticancer drugs and P-gp inhibitors has been …
Pinostrobin and tectochrysin conquer multidrug-resistant cancer cells via inhibiting P-glycoprotein ATPase
Enhanced drug efflux through ATP-binding cassette transporters, particularly P-glycoprotein
(P-gp), is a key mechanism underlying multidrug resistance (MDR). In the present study, we …
(P-gp), is a key mechanism underlying multidrug resistance (MDR). In the present study, we …
Design, synthesis, and bioactivity evaluation of novel indole-selenide derivatives as P-glycoprotein inhibitors against multi-drug resistance in MCF-7/ADR cell
Z Yang, D Luo, C Shao, H Hu, X Yang, Y Cai… - European Journal of …, 2024 - Elsevier
The inhibition of P-glycoprotein (P-gp) has emerged as an intriguing strategy for
circumventing multidrug resistance (MDR) in anticancer chemotherapy. In this study, we …
circumventing multidrug resistance (MDR) in anticancer chemotherapy. In this study, we …
Structure-based discovery of pyrimidine aminobenzene derivatives as potent oral reversal agents against P-gp-and BCRP-mediated multidrug resistance
Q Qiu, F Zou, H Li, W Shi, D Zhou… - Journal of Medicinal …, 2021 - ACS Publications
Overexpression of ATP binding cassette (ABC) transporters, including P-glycoprotein (P-gp)
and breast cancer resistance protein (BCRP), is an important factor leading to multidrug …
and breast cancer resistance protein (BCRP), is an important factor leading to multidrug …
Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer
The biggest challenge associated with cancer chemotherapy is the development of cross
multi-drug resistance to almost all anti-cancer agents upon chronic treatment. The major …
multi-drug resistance to almost all anti-cancer agents upon chronic treatment. The major …
[HTML][HTML] Novel application of rhein and its prodrug diacerein for reversing cancer-related multidrug resistance through the dual inhibition of P-glycoprotein efflux and …
YN Teng, MC Kao, SY Huang, TS Wu, TE Lee… - Biomedicine & …, 2022 - Elsevier
Multidrug resistance (MDR) is a multifactorial issue in cancer treatment. Drug efflux
transporters, particularly P-glycoprotein (P-gp), are major contributors to such resistance. In …
transporters, particularly P-glycoprotein (P-gp), are major contributors to such resistance. In …